PENGGUNAAN KELASI BESI DEFERASIROX DAN PENURUNAN KADAR FERRITIN SERUM PASIEN THALASSEMIA MAYOR ANAK

NURZA, MGS AMMAR AGUSTIAN and Athiah, Medina and Sinulingga, Sadakata (2024) PENGGUNAAN KELASI BESI DEFERASIROX DAN PENURUNAN KADAR FERRITIN SERUM PASIEN THALASSEMIA MAYOR ANAK. Undergraduate thesis, Sriwijaya University.

[thumbnail of RAMA_11201_04011282126058.pdf] Text
RAMA_11201_04011282126058.pdf - Accepted Version
Restricted to Repository staff only
Available under License Creative Commons Public Domain Dedication.

Download (2MB) | Request a copy
[thumbnail of RAMA_11201_04011282126058_TURNITIN.pdf] Text
RAMA_11201_04011282126058_TURNITIN.pdf - Accepted Version
Restricted to Repository staff only
Available under License Creative Commons Public Domain Dedication.

Download (7MB) | Request a copy
[thumbnail of RAMA_11201_04011282126058_0025068703_8991790024_01_front_ref.pdf] Text
RAMA_11201_04011282126058_0025068703_8991790024_01_front_ref.pdf - Accepted Version
Available under License Creative Commons Public Domain Dedication.

Download (1MB)
[thumbnail of RAMA_11201_04011282126058_0025068703_8991790024_02.pdf] Text
RAMA_11201_04011282126058_0025068703_8991790024_02.pdf - Accepted Version
Restricted to Repository staff only
Available under License Creative Commons Public Domain Dedication.

Download (970kB) | Request a copy
[thumbnail of RAMA_11201_04011282126058_0025068703_8991790024_03.pdf] Text
RAMA_11201_04011282126058_0025068703_8991790024_03.pdf - Accepted Version
Restricted to Repository staff only
Available under License Creative Commons Public Domain Dedication.

Download (494kB) | Request a copy
[thumbnail of RAMA_11201_04011282126058_0025068703_8991790024_04.pdf] Text
RAMA_11201_04011282126058_0025068703_8991790024_04.pdf - Accepted Version
Restricted to Repository staff only
Available under License Creative Commons Public Domain Dedication.

Download (452kB) | Request a copy
[thumbnail of RAMA_11201_04011282126058_0025068703_8991790024_05.pdf] Text
RAMA_11201_04011282126058_0025068703_8991790024_05.pdf - Accepted Version
Restricted to Repository staff only
Available under License Creative Commons Public Domain Dedication.

Download (217kB) | Request a copy
[thumbnail of RAMA_11201_04011282126058_0025068703_8991790024_06_ref.pdf] Text
RAMA_11201_04011282126058_0025068703_8991790024_06_ref.pdf - Bibliography
Restricted to Repository staff only
Available under License Creative Commons Public Domain Dedication.

Download (234kB) | Request a copy
[thumbnail of RAMA_11201_04011282126058_0025068703_8991790024_07_lamp.pdf] Text
RAMA_11201_04011282126058_0025068703_8991790024_07_lamp.pdf - Accepted Version
Restricted to Repository staff only
Available under License Creative Commons Public Domain Dedication.

Download (1MB) | Request a copy

Abstract

Background: Pediatric thalassemia major require lifelong blood transfusions to compensate inadequate erythrocyte. However, regular blood transfusions cause iron overload. In addition, pathologically in thalassemia, there is also iron accumulation due to faster hemolysis and ineffective erythropoiesis process. Iron overload is toxic for organ so that it must be removed using iron chelation, one of which is deferasirox. This study aims to determine the best dose of deferasirox to reduces serum ferritin in pediatric thalassemia major at Dr. Mohammad Hoesin Hospital Palembang. Methods: This descriptive observational study was conducted at Dr. Mohammad Hoesin Hospital Palembang from October to December 2024. There were 69 samples that met the inclusion criteria from total 208 samples. Data were analyzed using SPSS version 27 in the form of frequency distribution and grouping through ROC Analysis. Results: The characteristics of the samples were mostly in the age group of 10-18 years (49.3%), the majority were diagnosed with thalassemia ≤5 years (71%), and the majority had blood transfusions ≥12 times/year (59.4%). The greatest decrease in serum ferritin in the 31-40 mg/kg/day dose group (6.710.2µg/L), however, the number of samples who experienced a decrease in serum ferritin levels was greatest using the 21-30 mg/kg/day dose (57,8%) of the total samples that experienced a decrease ferritin serum Conclusion: The use of deferasirox doses in pediatric thalassemia major at Dr. Mohammad Hoesin Palembang Hospital which experienced the most decline was at a dose of 21-30 mg/kg/day. Keywords: Thalassemia, deferasirox, ferritin

Item Type: Thesis (Undergraduate)
Uncontrolled Keywords: Thalassemia, deferasirox, ferritin
Subjects: R Medicine > R Medicine (General) > R5-920 Medicine (General)
Divisions: 04-Faculty of Medicine > 11201-Medicine (S1)
Depositing User: MGS AMMAR AGUSTIAN NURZA
Date Deposited: 24 Dec 2024 05:06
Last Modified: 24 Dec 2024 05:06
URI: http://repository.unsri.ac.id/id/eprint/161388

Actions (login required)

View Item View Item